Innovent Biologics Inc - Asset Resilience Ratio

Latest as of December 2025: 2.37%

Innovent Biologics Inc (6IB) has an Asset Resilience Ratio of 2.37% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Innovent Biologics Inc short-term liquidity ratio to evaluate short-term liquidity relative to the company's equity base.

Liquid Assets

€886.74 Million

≈ $1.04 Billion USD Cash + Short-term Investments

Total Assets

€37.35 Billion

≈ $43.66 Billion USD All company assets

Resilience Assessment

Low

Financial Resilience Level

Asset Resilience Ratio Trend (2016–2025)

This chart shows how Innovent Biologics Inc's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see Innovent Biologics Inc (6IB) total assets.

Liquid Assets Composition Over Time

This chart breaks down Innovent Biologics Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Read Innovent Biologics Inc total liabilities for a breakdown of total debt and financial obligations.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	€0.00	0%
Short-term Investments	€886.74 Million	2.37%
Total Liquid Assets	€886.74 Million	2.37%

Asset Resilience Insights

Limited Liquidity: Innovent Biologics Inc maintains only 2.37% of assets in liquid form.
This low level may indicate efficient asset utilization but could pose risks during economic downturns.
The company has significant short-term investments, indicating active treasury management.

Innovent Biologics Inc Industry Peers by Asset Resilience Ratio

Compare Innovent Biologics Inc's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
argenx NV ADR NASDAQ:ARGX	Biotechnology	15.95%
Madrigal Pharmaceuticals Inc NASDAQ:MDGL	Biotechnology	62.31%
Shanghai RAAS Blood Products Co Ltd Class A SHE:002252	Biotechnology	2.03%
Halozyme Therapeutics Inc NASDAQ:HALO	Biotechnology	12.71%
Tubize-Fin BR:TUB	Biotechnology	2.50%
Aurinia Pharmaceuticals Inc NASDAQ:AUPH	Biotechnology	33.23%
Nanobiotix NASDAQ:NBTX	Biotechnology	4.71%
Innovita Biological Technology Co. Ltd. A SHG:688253	Biotechnology	65.12%

Annual Asset Resilience Ratio for Innovent Biologics Inc (2016–2025)

The table below shows the annual Asset Resilience Ratio data for Innovent Biologics Inc.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2025-12-31	2.37%	€886.74 Million ≈ $1.04 Billion	€37.35 Billion ≈ $43.66 Billion	+0.64pp
2024-12-31	1.74%	€375.56 Million ≈ $439.06 Million	€21.60 Billion ≈ $25.26 Billion	-34.01pp
2023-12-31	35.75%	€7.37 Billion ≈ $8.62 Billion	€20.63 Billion ≈ $24.12 Billion	-5.46pp
2022-12-31	41.21%	€7.25 Billion ≈ $8.47 Billion	€17.59 Billion ≈ $20.56 Billion	+37.24pp
2021-12-31	3.97%	€644.85 Million ≈ $753.90 Million	€16.24 Billion ≈ $18.99 Billion	+0.95pp
2020-12-31	3.02%	€357.30 Million ≈ $417.72 Million	€11.83 Billion ≈ $13.84 Billion	-28.37pp
2019-12-31	31.39%	€2.27 Billion ≈ $2.65 Billion	€7.23 Billion ≈ $8.45 Billion	-1.56pp
2017-12-31	32.94%	€809.48 Million ≈ $946.37 Million	€2.46 Billion ≈ $2.87 Billion	+5.16pp
2016-12-31	27.78%	€782.25 Million ≈ $914.53 Million	€2.82 Billion ≈ $3.29 Billion	--

pp = percentage points

About Innovent Biologics Inc

F:6IB Germany Biotechnology

Market Cap

$21.18 Billion

€18.11 Billion EUR

Market Cap Rank

#1416 Global

#318 in Germany

Share Price

€10.40

Change (1 day)

+2.83%

52-Week Range

€7.96 - €11.96

All Time High

€11.96